Special Feature Breast cancer research from bench to bedside

Breast Cancer

, Volume 17, Issue 2, pp 80-85

Breast cancer stem cells

  • Kazuharu KaiAffiliated withDivision of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Keio University
  • , Yoshimi ArimaAffiliated withDivision of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Keio University
  • , Toshio KamiyaAffiliated withDivision of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Keio University
  • , Hideyuki SayaAffiliated withDivision of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Keio University Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Since the initial discovery of leukemia stem cells nearly a decade ago, a great deal of cancer research has focused on the identification of cancer stem cells (CSCs) in many types of solid tumors, including breast cancer. Through analysis of cell surface markers and xenotransplant models, a subpopulation of putative human breast cancer stem cells (BCSCs) that is CD24-negative/CD44-positive (CD24/CD44+) and bears high aldehyde dehydrogenase 1 activity has been isolated in clinical samples of breast cancer tissues. Human BCSCs are considered to be derived from basal cells that reside in the basal membranes of alveolar units in human adult mammary glands. Furthermore, BCSCs have been shown to express higher levels of oxidative stress-responsive genes, which could confer part of their ability to resist anti-cancer therapy, than non-CSCs. The emerging picture of the biological properties of BCSCs would contribute for devising innovative therapies for breast cancer, targeting the intrinsic and extrinsic factors that maintain the BCSCs.

Keywords

Self-renewal Somatic (tissue-specific) stem cell Niche Epithelial to mesenchymal transition (EMT)